Medical-testing companies disagree on potential impact of gene patent ruling

Print Friendly, PDF & Email

Much has changed since 1990, when geneticist Mary Claire King first located the breast-cancer gene at the heart of the case the Supreme Court is hearing this spring. As genetic testing has entered everyday medicine, many companies offer a range of tests, and some sequence a patient’s entire genome seeking clues to disease. Figuring out who owns the rights to all those genes isn’t easy.

That is why some of the medical-testing industry’s bigger players are finding gene patents can be as much a hindrance as a help, even if they own a few themselves. Should the high court decide that individual genes are products of nature and can’t be patented, they see equal or faster growth in the already fast-growing business.

View the original article here: Gene Patents Face Reckoning

Outbreak Featured
Infographic: Growing human embryos — How long should researchers watch human development play out in a dish?

Infographic: Growing human embryos — How long should researchers watch human development play out in a dish?

In May, the International Society for Stem Cell Research (ISSCR) released new guidelines that relaxed the 14-day rule, taking away ...
Are GMOs and pesticides threatening bees?

Are GMOs and pesticides threatening bees?

First introduced in 1995, neonicotinoids ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.